Transaction #2007 · Form 4 · 0001104659-25-101609
iBio, Inc. · Stock award · Stock Option (right to buy)
iBio, Inc. · Transacted October 20, 2025 · Filed October 22, 2025
What does this filing report?
An SEC Form 4 filing for iBio, Inc. records a stock award involving Stock Option (right to buy) on October 20, 2025. The reported quantity was 75,000. The filing date is October 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- iBio, Inc.
- Company CIK
- 0001420720
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 75,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 75,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 22, 2025, 6:29 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Duran Felipe ↗
Chief Financial Officer
CIK 0001964267
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 75,000
- Conversion / exercise price
- 0.893
- Exercise date
- October 20, 2026
- Expiration date
- October 19, 2035
Filing footnotes & remarks
- F1
- These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.